This report examines the clinical utility of genetic testing for diagnosis of hereditary leiomyomatosis and renal cell cancer (HLRCC) in symptomatic patients and their at-risk family members. The evidence for the use of genetic testing is evaluated with respect to screening for potential HLRCC patients, renal cancer surveillance and early detection, and the fertility impact of and morbidity from multiple uterine leiomyoma.
If you have a Hayes login, click here to view the full report on the Knowledge Center.